Myasthenia Gravis
Myasthenia gravis (MG) is a rare neuromuscular disorder that causes weakness in the skeletal muscles, which can lead to difficulties in movement, breathing, and swallowing. Symptoms often fluctuate and may worsen with activity.
Nipocalimab for Children with Generalized Myasthenia Gravis
We are studying a new treatment for children aged 2 to 17 with generalized myasthenia gravis who are not getting enough benefit from their current therapy. The trial will help us learn about its safety and effectiveness.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 2 and 17 years old?
- Do you have myasthenia gravis (MG) with muscle weakness?
- Have you had a positive test for anti-AChR or anti-MuSK antibodies?
- Are you currently taking any medications like eculizumab or other immune agents?
- Do you have any severe health issues like uncontrolled liver disease or heart problems?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Jnj-80202135
Nipocalimab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Leiden University Medical Center
Neurologie
Leiden, Netherlands
Uniwersyteckie Centrum Kliniczne
Klinika Neurologii Rozwojowej
Wrzeszcz Dolny, Poland
Sponsor: Janssen - Cilag International
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.